Cancer Pain and Symptom Management: Drug Therapy
The symptoms of pancreatic cancer are varied, based upon the location of the disease. However, these symptoms are almost always caused by mass effect of the tumor compressing the vasculature, lymphatics, or other organs rather than disruption of exocrine or endocrine pancreatic function. Classic symptoms of pancreatic cancer include pain, jaundice, and weight loss (Table 25.1) (1). Since early symptoms are usually nonspecific, they may go unrecognized for some time, and most pancreatic cancers are advanced at the time of diagnosis. In addition to the symptoms produced by the tumor itself, pancreatic cancer treatments are associated with significant complications. The following disease- and/or treatment-related symptoms are reviewed, along with strategies for their management: pain, nausea and vomiting, diarrhea, and constipation.
KeywordsPancreatic Cancer Neuropathic Pain Clin Oncol Cancer Pain Advanced Pancreatic Cancer
Unable to display preview. Download preview PDF.
- 1.DiMagno EP. 1992, Cancer of the pancreas and biliary tract. In: Winawer SJ (ed.) Management of gastrointestinal disease. Gower Medical Publishing, New York.Google Scholar
- 5.Evans DB, Abbruzzese JL, Willett CG. 2001, Cancer of the pancreas. In: DeVita VT, Hellman S, Rosenberg SA (eds.) Cancer: principles and practice of oncology, 6th ed. Philadelphia, Lippincott Williams & Wilkins, 1126–1161.Google Scholar
- 10. Clinical Practice Guideline in Oncology v.2.2006 Antiemesis. NCCN, 2006 (Accessed 05/20/06).Google Scholar
- 11.Beckwith M, Mullin S. 2001, Prevention and management of chemotherapy-induced nausea and vomiting, part 1. Hospital Pharmacy 36:67–80.Google Scholar
- 12. Kris M, Hesketh P, Somerfield M, et al. 2006, American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24, epub May 22.Google Scholar
- 15.Hesketh P, Navari R, Grote T, et al. 1996, Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 14: 2242–2249.PubMedGoogle Scholar
- 16.Navari R, Gandara D, Hesketh P, et al. 1995, Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Gransistron Study Group. J Clin Oncol 13:1242–1248.Google Scholar
- 36.American Society of Health-System Pharmacists. 1999, ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm 56:729–764.Google Scholar